866-997-4948(US-Canada Toll Free)

Metastatic Lung Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Cancer

No. of Pages : 68 Pages


Metastatic Lung Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Metastatic Lung Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Metastatic Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Lung Cancer.
  • A review of the Metastatic Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Lung Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Metastatic Lung Cancer 8
Metastatic Lung Cancer Therapeutics under Development by Companies 10
Metastatic Lung Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Metastatic Lung Cancer Therapeutics Products under Development by Companies 17
Metastatic Lung Cancer Therapeutics Products under Investigation by Universities/Institutes 18
Companies Involved in Metastatic Lung Cancer Therapeutics Development 19
Abbott Laboratories 19
Sanofi-Aventis 20
Pfizer Inc. 21
Transgene SA 22
Vascular Biogenics Ltd. 23
NewLink Genetics Corporation 24
Metastatic Lung Cancer Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
TG-4010 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
VB-111 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
sargramostim - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Sunitinib + Erlotinib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Taxol + Cisplatin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Taxotere + Eloxatin + Avastin - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Aflibercept + Docetaxel - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cyclophosphamide + Vaccine Therapy - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 43
Carboplatin + TS-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Cisplatin + Thiosulfate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Decitabine + Romidepsin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
isolated perfusion + paclitaxel - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MVF-HER-2(628-647)-CRL 1005 Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GSK1363089 + Erlotinib Hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
romidepsin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NLG8189 + Taxotere - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CpG DNA Lipoplex - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Oncoprex - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ABT-888 + Carboplatin + Paclitaxel - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Metastatic Lung Cancer Therapeutics Drug Profile Updates 58
Metastatic Lung Cancer Therapeutics Discontinued Products 61
Metastatic Lung Cancer Therapeutics - Dormant Products 62
Metastatic Lung Cancer Product Development Milestones 63
Featured News & Press Releases 63
Aug 13, 2012: Health Canada Approves TARCEVA As First-Line Therapy For Treatment Of Non-Small Cell Lung Cancer 63
Jun 20, 2011: Momenta Announces Publication Of Preclinical Results Of Oncology Drug M402 In PLoS One 63
Jun 10, 2011: CureVac Presents Promising New Data For Lung Cancer Vaccine CV9201 At ASCO Conference 64
May 19, 2011: VBL Therapeutics Presents Preclinical Data For VB-111 At 14th Annual ASGCT Meeting 64
Nov 10, 2010: Silence Reports Positive Preclinical Research Findings Of Atu027 In Pulmonary Metastasis Animal Models 65

Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Table


Number of Products Under Development for Metastatic Lung Cancer, H2 2012 8
Products under Development for Metastatic Lung Cancer Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Abbott Laboratories, H2 2012 19
Sanofi-Aventis, H2 2012 20
Pfizer Inc., H2 2012 21
Transgene SA, H2 2012 22
Vascular Biogenics Ltd., H2 2012 23
NewLink Genetics Corporation, H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Metastatic Lung Cancer Therapeutics Drug Profile Updates 58
Metastatic Lung Cancer Therapeutics Discontinued Products 61
Metastatic Lung Cancer Therapeutics Dormant Products 62

List of Chart


Number of Products under Development for Metastatic Lung Cancer, H2 2012 8
Products under Development for Metastatic Lung Cancer Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *